Permanent Prostate Brachytherapy Monotherapy With I-125 for Low- and Intermediate-Risk Prostate Cancer: Outcome in 966 Patients

被引：4
|
作者：
Funk, R. K. [1 ]
Davis, B. J. [1 ]
Mynderse, L. A. [1 ]
Wilson, T. M. [1 ]
Deufel, C. L. [1 ]
Furutani, K. M. [1 ]
Pisansky, T. M. [1 ]
Haddock, M. G. [1 ]
Choo, C. R. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2015年 / 93卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2015.07.1088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2535
引用
收藏
页码：E213 / E214
页数：2
相关论文
共 50 条
  • [41] The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL
    Dallas, Nicola L.
    Malone, Peter R.
    Jones, Adam
    Doggart, Andrew J.
    McConway, Kevin J.
    Rogers, Paul B.
    BJU INTERNATIONAL, 2012, 110 (03) : 383 - 390
  • [42] EVALUATION OF DOSIMETRIC PARAMETERS AND DISEASE RESPONSE AFTER 125IODINE TRANSPERINEAL BRACHYTHERAPY FOR LOW- AND INTERMEDIATE-RISK PROSTATE CANCER
    Morris, W. James
    Keyes, Mira
    Palma, David
    McKenzie, Michael
    Spadinger, Ingrid
    Agranovich, Alex
    Pickles, Tom
    Liu, Mitchell
    Kwan, Winkle
    Wu, Jonn
    Lapointe, Vince
    Berthelet, Eric
    Pai, Howard
    Harrison, Robert
    Kwa, William
    Bucci, Joe
    Racz, Violet
    Woods, Ryan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (05): : 1432 - 1438
  • [43] Long-Term Efficacy and Toxicity of Low-Dose-Rate 125I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer
    Kittel, Jeffrey A.
    Reddy, Chandana A.
    Smith, Kristin L.
    Stephans, Kevin L.
    Tendulkar, Rahul D.
    Ulchaker, James
    Angermeier, Kenneth
    Campbell, Steven
    Stephenson, Andrew
    Klein, Eric A.
    Wilkinson, D. Allan
    Ciezki, Jay P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (04): : 884 - 893
  • [44] Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: Outcome and toxicity
    Yamada, Yasuhiro
    Masui, Koji
    Iwata, Tsuyoshi
    Naitoh, Yasuyuki
    Yamada, Kei
    Miki, Tsuneharu
    Okihara, Koji
    BRACHYTHERAPY, 2015, 14 (02) : 118 - 123
  • [45] RESULTS AFTER 8 YEARS OF CURATIVE I-125 BRACHYTHERAPY IN 1023 CONSECUTIVE PATIENTS WITH LOW, INTERMEDIATE AND HIGH RISK PROSTATE CANCER
    Zimmermann, J.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S87 - S87
  • [46] I-125 permanent prostate brachytherapy boost and three-dimensional conformal fast neutron radiotherapy for intermediate prognosis prostate cancer
    Frazier, AJ
    Ahmad, F
    Udelev, M
    Cher, M
    Wood, D
    Forman, JD
    CANCER JOURNAL, 2001, 7 (06): : 550 - 551
  • [47] Impact of primary Gleason grade 4 on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer
    Saika, T.
    Uesugi, T.
    Edamura, K.
    Kobuke, M.
    Nose, H.
    Ebara, S.
    Nasu, Y.
    Katayama, N.
    Yanai, H.
    Kumon, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [48] PRIMARY GLEASON GRADE 4 IMPACTS ON BIOCHEMICAL RECURRENCE AFTER PERMANENT INTERSTITIAL BRACHYTHERAPY IN JAPANESE PATIENTS WITH LOW- OR INTERMEDIATE-RISK PROSTATE CANCER
    Saika, Takashi
    Uesugi, Tatsuya
    Edamura, Kohei
    Nose, Hiroyuki
    Kobuke, Makoto
    Ebara, Shin
    Katayama, Norihisa
    Yanai, Hiroyuki
    Nasu, Yasutomo
    Kumon, Hiromi
    JOURNAL OF UROLOGY, 2011, 185 (04): : E523 - E523
  • [49] Survival of Low-Risk and Intermediate-Risk Prostate Cancer Patients Treated with IMRT Or Brachytherapy
    Podder, T.
    Dey, A.
    Datta, S.
    Biswas, T.
    MEDICAL PHYSICS, 2020, 47 (06) : E318 - E318
  • [50] LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients
    Boehle, Andreas
    Zywietz, Dorothea
    Robrahn-Nitschke, Irina
    Lusch, Achim
    Koenig, Inke R.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (11) : 454.e17 - 454.e24
12345